Beta Bionics (NASDAQ:BBNX) Director Sells $39,354.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 2,811 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00. Following the sale, the director directly owned 27,400 shares of the company’s stock, valued at approximately $383,600. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $19,880.10.

Beta Bionics Price Performance

Beta Bionics stock remained flat at $13.89 during trading on Friday. The company had a trading volume of 1,006,729 shares, compared to its average volume of 1,142,134. The firm has a 50 day simple moving average of $10.88 and a 200 day simple moving average of $17.21. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The company has a market capitalization of $618.97 million, a P/E ratio of -9.20 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The business had revenue of $27.63 million during the quarter. Equities analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Beta Bionics in the first quarter valued at $95,000. Goldman Sachs Group Inc. bought a new position in Beta Bionics in the 1st quarter worth about $715,000. Woodline Partners LP bought a new position in Beta Bionics in the 1st quarter worth about $1,530,000. Strs Ohio bought a new position in Beta Bionics in the 1st quarter worth about $29,000. Finally, Rhumbline Advisers bought a new position in Beta Bionics in the 1st quarter worth about $158,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on BBNX. Robert W. Baird decreased their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Truist Financial reduced their price objective on Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Leerink Partners reduced their price objective on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Finally, The Goldman Sachs Group reduced their price objective on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.